NCT05277532 Effect of Circadian Rhythm and Physical Exercise in Overweight Type 1 Diabetes Patients
| NCT ID | NCT05277532 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Karolinska Institutet |
| Condition | Type 1 Diabetes |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2022-05-18 |
| Primary Completion | 2025-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2022-05-18 with a primary completion date of 2025-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cardiometabolic risk in patients with abdominal obesity and type 1 diabetes can be moderated by life style modifications. There is an intimate link between gene regulation and circadian rhythm in mediating response to exercise in a variety of insulin sensitive organs. The aim of this project is to evaluate, by intervention, the interplay of circadian rhythm and high intensity interval training (HIIT) on glucose control and skeletal muscle metabolism in patients with overweight with or without type 1 diabetes (T1D).
Eligibility Criteria
Inclusion Criteria: * BMI 25-30 * type 1 diabetes or healthy subjects Exclusion Criteria: * nicotine usage, * cardiovascular disease (CVD), * blood pressure \>160/95, * pregnancy, * treatment with other pharmaceutical drugs than insulin, stable dose of thyroid hormone, statins, and antihypertensive drugs (excluding beta blockers). Additional exclusion criteria for diabetes subjects: * diabetes duration less than 6 months, * proliferative or severe non-proliferative retinopathy, * chronic kidney disease with glomerular filtration rate (GFR) \<60 ml/min,
Contact & Investigator
Ingrid Dahlman, Professor
PRINCIPAL INVESTIGATOR
Karolinska Institutet
Frequently Asked Questions
Who can join the NCT05277532 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Type 1 Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05277532 currently recruiting?
Yes, NCT05277532 is actively recruiting participants. Contact the research team at eva.toft@ki.se for enrollment information.
Where is the NCT05277532 trial being conducted?
This trial is being conducted at Stockholm, Sweden.
Who is sponsoring the NCT05277532 clinical trial?
NCT05277532 is sponsored by Karolinska Institutet. The principal investigator is Ingrid Dahlman, Professor at Karolinska Institutet. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.